You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

indolent lymphomas, neuroendocrine tumors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Locally Advanced Malignant Solid Tumor Trial run by the NCI (p97

Withdrawn
  • Aggressive Non-Hodgkin Lymphoma
  • +3 more
  • p97 Inhibitor CB-5339 Tosylate
  • Bethesda, Maryland
  • +1 more
Aug 27, 2021

Melanoma, NSCLC, Breast Cancer Trial in United States (CDX-1140, CDX-301, Pembrolizumab)

Completed
  • Melanoma
  • +25 more
  • Scottsdale, Arizona
  • +10 more
Sep 27, 2022

Non-functional Neuroendocrine Tumors of Pancreatic Body and Tail

Recruiting
  • Non Functioning Pancreatic Endocrine Tumor
  • Histopathological review, long-term prognosis and quality of life follow-up
  • Shanghai, Shanghai, China
    Department of Pancreatic Surgery, Fudan University Shanghai Canc
Jun 8, 2023

Development of New Personalised 3D Preclinical Models of

Recruiting
  • Pancreatic Neuroendocrine Tumor
    • Milan, MI, Italy
      IRCCS San Raffele Institute
    Nov 2, 2023

    Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor Trial in São Paulo (Tamoxifen)

    Active, not recruiting
    • Neuroendocrine Tumors
    • +2 more
    • Tampa, Florida
    • +1 more
    Jan 13, 2023

    Neuroendocrine Tumors Trial in Toronto (F18-FDG)

    Recruiting
    • Neuroendocrine Tumors
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    May 20, 2022

    Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

    Completed
    Has Results
    • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Sep 20, 2022

    Advanced Solid Tumors With Neuroendocrine Differentiation Trial (surufatinib?serplulimab)

    Not yet recruiting
    • Advanced Solid Tumors With Neuroendocrine Differentiation
    • (no location specified)
    Nov 27, 2023

    Midgut Carcinoid Tumor, Biliary Stones Trial in Spain (Primary tumor surgery, Primary tumor surgery (bowel resection) combined

    Recruiting
    • Midgut Carcinoid Tumor
    • Biliary Stones
    • Primary tumor surgery
    • Primary tumor surgery (bowel resection) combined with prophylactic cholecystectomy
    • Badalona, Barcelona, Spain
    • +5 more
    Jul 6, 2022

    Imaging Features in Invasiveness and Prognosis of Pituitary

    Recruiting
    • Pituitary Adenoma
    • Neuroendocrine Tumors
    • diagnosed and treated reasonably according to the clinical guidelines and clinical pathways
    • Guangzhou, Guangdong, China
      endocrinology department of the first affiliated hospital of Sun
    Aug 24, 2023

    NHWD-870 in Advanced Solid Tumors or Lymphomas Carrying NUT

    Recruiting
    • Advanced Solid Tumors or Lymphomas
    • Changsha, Hunan, China
      Hunan Provincal Tumor Hospital
    Oct 5, 2023

    Ganglioneuroblastoma, Ganglioneuroma, Metastatic Neuroblastoma Trial in Rochester (Computed Tomography, Gallium Ga 68-DOTATATE,

    Recruiting
    • Ganglioneuroblastoma
    • +2 more
    • Computed Tomography
    • +2 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jan 30, 2023

    Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma Trial in France (Atezolizumab, Obinutuzumab,

    Completed
    • Follicular Lymphoma
    • +3 more
    • Angers, France
    • +24 more
    Jan 9, 2023

    Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma Trial (177Lu-DOTATOC)

    Not yet recruiting
    • Neuroendocrine Tumors
    • +2 more
    • (no location specified)
    Sep 13, 2023

    Solid Tumor, Classic Hodgkin Lymphoma Trial in China (IMM01, Tislelizumab)

    Recruiting
    • Solid Tumor
    • Classic Hodgkin Lymphoma
    • Hangzhou, China
    • +4 more
    Apr 18, 2023

    NSCLC, Gastric Carcinoma, Gastroesophageal Junction Carcinoma Trial in Worldwide (SEA-TGT, sasanlimab)

    Recruiting
    • Non-small Cell Lung Cancer
    • +11 more
    • Birmingham, Alabama
    • +32 more
    Jan 4, 2023

    Surufatinib in G3 Neuroendocrine Tumors

    Not yet recruiting
    • Neuroendocrine Tumor Grade 3
    • (no location specified)
    Aug 2, 2023

    Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1 Trial ([203Pb]VMT-a-NET, SPECT/CT)

    Enrolling by invitation
    • Neuroendocrine Tumor Grade 2
    • Neuroendocrine Tumor Grade 1
    • Iowa City, Iowa
      The University of Iowa
    Dec 9, 2022

    Advanced Gastroenteropancreatic Neuroendocrine Tumor Trial (Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide,

    Not yet recruiting
    • Advanced Gastroenteropancreatic Neuroendocrine Tumor
    • Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide
    • long-acting Octreotide.
    • (no location specified)
    May 22, 2023

    T-cell Lymphoma, CLL/SLL Trial in Birmingham (Tazemetostat, Acalabrutinib and Tazemetostat)

    Not yet recruiting
    • T-cell Lymphoma
    • CLL/SLL
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Aug 11, 2023

    Neuroendocrine Tumors Trial in Beijing (Surufatinib Combined With Temozolomide and S-1)

    Not yet recruiting
    • Neuroendocrine Tumors
    • Surufatinib Combined With Temozolomide and S-1
    • Beijing, Beijing, China
      Cancer Institute and Hospital, Chinese Academy of Medical Scienc
    Sep 8, 2023

    Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma Trial in Shanghai (individualized mRNA

    Not yet recruiting
    • Adrenal Cortical Carcinoma
    • +3 more
    • individualized mRNA neoantigen vaccine (mRNA-0523-L001)
    • Shanghai, Shanghai, China
      Ruijin hospital, Shanghai Jiao-Tong University School of Medicin
    Nov 19, 2023

    Lymphoma Trial in Houston (Ibritumomab Tiuxetan (Zevalin), Rituximab)

    Completed
    Has Results
    • Lymphoma
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Aug 30, 2022

    Metastatic Neuroendocrine Tumor Trial (Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate)

    Not yet recruiting
    • Metastatic Neuroendocrine Tumor
    • Biospecimen Collection
    • +4 more
    • (no location specified)
    Feb 10, 2023

    Multi-dimensional Fragmentomic Assay for Early Detection of

    Not yet recruiting
    • Pancreatic Neuroendocrine Tumor
    • Fragmentomic profiles of plasma cfDNA
    • (no location specified)
    Apr 27, 2023